Hernic/Hecn30227 injection in healthy people and chronic hepatitis B patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 trial evaluates the safety, pharmacokinetics, immunogenicity, and preliminary efficacy signals of single- and multiple-dose HECN30227 injections. Participants include healthy volunteers and adults with chronic hepatitis B who are already on stable nucleos(t)ide analogue therapy. The study compares HECN30227 against placebo across various dosing regimens (SAD and MAD) to determine tolerability and basic biological responses. Key assessments include vital signs, labs, ECG, imaging, and liver function, with adherence to contraception requirements for those of reproductive potential. The trial is led by Sunshine Lake Pharma with enrollment at The Second Affiliated Hospital of Anhui Medical University in Hefei, China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects must understand and comply with the study procedures, voluntarily participate, and sign the informed consent form.
2. Male subjects must weigh at least 50 kg; female subjects must weigh at least 45 kg.
3. Vital signs, physical examination, laboratory tests, electrocardiography (ECG), chest X-ray, and abdominal ultrasound (liver, gallbladder, spleen, pancreas, and both kidneys) are normal, or abnormalities are judged by the investigator to be clinically insignificant.
4. Female subjects of childbearing potential or male subjects must agree to use effective contraception from the time of signing the informed consent form until 6 months after the last dose of study drug.
5. Subjects must have received stable treatment with nucleos(t)ide analogues (NAs) (e.g., entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide) for at least 6 months prior to screening.
6. HBV DNA \< 90 IU/mL at screening.
7. HBsAg \> 100 IU/mL at screening.
8. Serum ALT and AST ≤ 2 × ULN, and total serum bilirubin ≤ 2 × ULN at screening and baseline.

Exclusion Criteria:

1. Subjects who have undergone major surgery within 3 months prior to screening, or plan to undergo surgery during the study period.
2. Subjects with a history of allergy to the study drug or any of its components, or with allergic diathesis (allergic to two or more types of drugs or foods).
3. Subjects with a history of alcohol abuse within 1 year prior to screening , or those with a positive blood alcohol test result prior to dosing.
4. Subjects with a history of drug abuse or use of illicit drugs within 1 year prior to screening, or those with a positive urine drug screening result prior to dosing.
5. Subjects who donated blood ≥200 mL, or donated any blood component, or suffered a total blood loss ≥200 mL for any reason within 3 months prior to screening; or those with a history of blood transfusion or blood product administration.
6. Subjects who participated in another clinical trial within 3 months prior to screening.
7. Subjects who develop an acute illness (e.g., acute respiratory disease) or receive concomitant medication from the time of signing the informed consent form to prior to the first dose.
8. Subjects who are breastfeeding or have a positive serum pregnancy test result.
9. Subjects with significant hepatic fibrosis or liver cirrhosis.
10. Subjects with a history of hepatic decompensation manifestations or disease at screening or in the past, including but not limited to ruptured esophageal and gastric variceal bleeding, ascites, hepatic encephalopathy, etc.
11. Subjects diagnosed with any malignant tumor within 5 years prior to screening , or those assessed to have potential malignant tumors at present.
12. Subjects with international normalized ratio (INR) \>1.5, or platelet count \<90×10⁹/L, or serum albumin \<35 g/L at screening.
13. Subjects with alpha-fetoprotein (AFP) \>50 ng/mL at screening.
14. Subjects with endogenous creatinine clearance (CLcr) \<60 mL/min/1.73 m² at screening.
15. Subjects receiving, or who have received any interferon-containing regimen or immunosuppressive therapy within 1 year prior to screening.
16. Subjects whom the investigator considers unsuitable for participation in this trial for any other reasons.

Where it's running

• The Second Affiliated Hospital of Anhui Medical University
  Hefei, China Recruiting

Study contacts

• Study coordinator: wei Hu
• Email: hwgcp@ayefy.com
• Phone: 13856086475

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single-cell and spatial mapping of liver degeneration and regeneration

  This project will try to use single-cell and spatial omics on preoperative blood and discarded liver tissue from people having liver surgery or biopsy to map how cells change during fatty liver, HBV infection, fibrosis, and cirrhosis.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07265544

• Immune changes over time in people with chronic hepatitis B

  This project will follow untreated people aged 1–80 with chronic hepatitis B every six months to see if changes in HBV-specific immunity and age are linked to how the infection progresses.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07137247

• HBV Universal vs Point-of-Ccare Antiviral Prophylaxis to Prevent Mother-to-Child Transmission

  This trial tests whether giving antiviral prophylaxis to all HBsAg-positive pregnant women is as effective as a selective approach guided by a rapid HBcrAg test in preventing mother-to-child transmission of hepatitis B.

  Recruiting ANRS, Emerging Infectious Diseases · Haiphong · NCT07054359

• Evaluating new biomarkers for chronic Hepatitis B infection management

  This study is testing new blood markers to see if they can help doctors better manage chronic Hepatitis B and predict serious health issues for patients receiving care at a hospital.

  Recruiting Assistance Publique - Hôpitaux de Paris · Créteil, Créteil · NCT06906016

• Non-invasive approach to assess liver fibrosis in chronic hepatitis B patients

  This study is testing a new way to see if liver stiffness measurements can help predict if liver damage improves in people with chronic hepatitis B who have been treated with antiviral therapy.

  Recruiting Beijing Friendship Hospital · Beijing · NCT06874127

• Evaluating a new combination therapy for chronic Hepatitis B infection

  This study is testing a new combination treatment for adults with chronic Hepatitis B who are already on medication to see if it works better than the standard treatment alone.

  Recruiting at 14 sites Phase 2 Brii Biosciences Limited · Beijing, Beijing Municipality and 13 other locations · NCT06650852

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.